What Happened
Hims & Hers Health, Inc. reported mixed financial results for the fourth quarter of 2025, revealing earnings per share of $0.08, surpassing analysts’ expectations of $0.04. Revenue for the quarter was $617.8 million, slightly below the anticipated $619 million, but reflecting a year-on-year growth of 28.4%. The company also provided a lukewarm guidance for the upcoming year, projecting revenue between $2.7 billion and $2.9 billion, which is in line with analysts’ expectations of $2.74 billion.
Why It Matters
The earnings report comes amid significant legal challenges for Hims & Hers, particularly related to its recent rollout of a copycat version of Novo Nordisk’s Wegovy pill. The company is facing a patent infringement lawsuit from Novo and potential charges from the Department of Justice. This legal turmoil has contributed to a decline in Hims stock, which has dropped over 50% since the beginning of the year, with more than 30% of that decline occurring after the announcement of the Wegovy pill copies.
What’s Next
Looking ahead, Hims & Hers anticipates revenue guidance of $612.5 million for the first quarter of 2026, which is below analysts’ estimates of $649 million. The company is also projecting adjusted EBITDA of $337.5 million for the upcoming financial year, falling short of the expected $356.1 million. As the weight loss segment faces uncertainty, Hims & Hers is focusing on expanding into new treatment areas to stabilize its market position.
